Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Mitochondrial Respiration in Human Colorectal and Breast Cancer Clinical Material Is Regulated Differently.

Koit A, Shevchuk I, Ounpuu L, Klepinin A, Chekulayev V, Timohhina N, Tepp K, Puurand M, Truu L, Heck K, Valvere V, Guzun R, Kaambre T.

Oxid Med Cell Longev. 2017;2017:1372640. doi: 10.1155/2017/1372640. Epub 2017 Jul 11.

2.

Mammography use and mode of detection among breast cancer patients in Estonia.

Innos K, Valvere V, Padrik P, Eelma E, Kütner R, Lehtsaar J, Tekkel M.

Women Health. 2016;56(2):129-40. doi: 10.1080/03630242.2015.1086468. Epub 2015 Sep 1.

PMID:
26327255
3.

Sex differences in cancer survival in Estonia: a population-based study.

Innos K, Padrik P, Valvere V, Aareleid T.

BMC Cancer. 2015 Feb 19;15:72. doi: 10.1186/s12885-015-1080-9.

4.

Diagnostic significance of alternative splice variants of REST and DOPEY1 in the peripheral blood of patients with breast cancer.

Lend AK, Kazantseva A, Kivil A, Valvere V, Palm K.

Tumour Biol. 2015 Apr;36(4):2473-80. doi: 10.1007/s13277-014-2860-6. Epub 2014 Nov 26.

PMID:
25424701
5.

An in situ study of bioenergetic properties of human colorectal cancer: the regulation of mitochondrial respiration and distribution of flux control among the components of ATP synthasome.

Kaldma A, Klepinin A, Chekulayev V, Mado K, Shevchuk I, Timohhina N, Tepp K, Kandashvili M, Varikmaa M, Koit A, Planken M, Heck K, Truu L, Planken A, Valvere V, Rebane E, Kaambre T.

Int J Biochem Cell Biol. 2014 Oct;55:171-86. doi: 10.1016/j.biocel.2014.09.004. Epub 2014 Sep 10.

PMID:
25218857
6.

Identifying women at risk for delayed presentation of breast cancer: a cross-sectional study in Estonia.

Innos K, Padrik P, Valvere V, Eelma E, Kütner R, Lehtsaar J, Tekkel M.

BMC Public Health. 2013 Oct 9;13:947. doi: 10.1186/1471-2458-13-947.

7.

Metabolic control analysis of respiration in human cancer tissue.

Kaambre T, Chekulayev V, Shevchuk I, Tepp K, Timohhina N, Varikmaa M, Bagur R, Klepinin A, Anmann T, Koit A, Kaldma A, Guzun R, Valvere V, Saks V.

Front Physiol. 2013 Jun 28;4:151. doi: 10.3389/fphys.2013.00151. Print 2013.

8.

Time trends in population-based breast cancer survival in Estonia: analysis by age and stage.

Baburin A, Aareleid T, Padrik P, Valvere V, Innos K.

Acta Oncol. 2014 Feb;53(2):226-34. doi: 10.3109/0284186X.2013.806992. Epub 2013 Jun 14.

PMID:
23767956
9.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.

Lancet. 2013 Mar 9;381(9869):805-16. Erratum in: Lancet. 2013 Mar 9;381(9869):804.

10.

Metabolic control analysis of cellular respiration in situ in intraoperational samples of human breast cancer.

Kaambre T, Chekulayev V, Shevchuk I, Karu-Varikmaa M, Timohhina N, Tepp K, Bogovskaja J, Kütner R, Valvere V, Saks V.

J Bioenerg Biomembr. 2012 Oct;44(5):539-58. doi: 10.1007/s10863-012-9457-9. Epub 2012 Jul 27.

PMID:
22836527
11.

Adjuvant trastuzumab in HER2-positive breast cancer.

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group.

N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383.

12.

Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.

Curran D, Pozzo C, Zaluski J, Dank M, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Bugat R.

Qual Life Res. 2009 Sep;18(7):853-61. doi: 10.1007/s11136-009-9493-z. Epub 2009 Jul 1.

13.

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.

Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Cisar L, Wang K, Bugat R.

Ann Oncol. 2008 Aug;19(8):1450-7. doi: 10.1093/annonc/mdn166. Epub 2008 Jun 16.

PMID:
18558665
14.

Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study.

Pozzo C, Barone C, Szanto J, Padi E, Peschel C, Bükki J, Gorbunova V, Valvere V, Zaluski J, Biakhov M, Zuber E, Jacques C, Bugat R.

Ann Oncol. 2004 Dec;15(12):1773-81.

PMID:
15550582
15.

Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer.

Luoma ML, Hakamies-Blomqvist L, Sjöström J, Pluzanska A, Ottoson S, Mouridsen H, Bengtsson NO, Bergh J, Malmström P, Valvere V, Tennvall L, Blomqvist C.

Eur J Cancer. 2003 Jul;39(10):1370-6.

PMID:
12826039
16.

Tumour microvessel density as predictor of chemotherapy response in breast cancer patients.

Tynninen O, Sjöström J, von Boguslawski K, Bengtsson NO, Heikkilä R, Malmström P, Ostenstad B, Wist E, Valvere V, Saksela E, Paavonen T, Blomqvist C.

Br J Cancer. 2002 Jun 17;86(12):1905-8.

17.

Physical performance, toxicity, and quality of life as assessed by the physician and the patient.

Luoma ML, Hakamies-Blomqvist L, Sjöström J, Mouridsen H, Pluzanska A, Malmström P, Bengtsson NO, Hultborn R, Ostenstaad B, Mjaaland I, Valvere V, Wist E, Baldursson G, Ahigren J, Blomqvist C.

Acta Oncol. 2002;41(1):44-9.

PMID:
11990517
18.

The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer.

Sjöström J, Blomqvist C, von Boguslawski K, Bengtsson NO, Mjaaland I, Malmström P, Ostenstadt B, Wist E, Valvere V, Takayama S, Reed JC, Saksela E.

Clin Cancer Res. 2002 Mar;8(3):811-6.

19.

C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer.

Sjöström J, Collan J, von Boguslawski K, Franssila K, Bengtsson NO, Mjaaland I, Malmström P, Østenstad B, Wist E, Valvere V, Bergh J, Skiöld-Petterson D, Saksela E, Blomqvist C.

Eur J Cancer. 2002 Mar;38(4):535-42.

PMID:
11872346
20.

Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.

Sjöström J, Blomqvist C, Heikkilä P, Boguslawski KV, Räisänen-Sokolowski A, Bengtsson NO, Mjaaland I, Malmström P, Ostenstadt B, Bergh J, Wist E, Valvere V, Saksela E.

Clin Cancer Res. 2000 Aug;6(8):3103-10.

Supplemental Content

Loading ...
Support Center